Logo

Abbvie Entered into an Exclusive Collaboration with Plexium to Develop and Commercialize Novel Targeted Protein Degradation Therapies for Neurological Conditions

Share this

Abbvie Entered into an Exclusive Collaboration with Plexium to Develop and Commercialize Novel Targeted Protein Degradation Therapies for Neurological Conditions

Shots:

  • Plexium received an up front & is eligible to receive an additional fee along with royalties on commercialized products & gets an option to participate in product development in return of higher royalty
  • AbbVie gets the option to select programs for additional R&D activities & will be responsible for the development and commercialization of products globally that emerge from the collaboration. Plexium will be responsible to conduct the preclinical research activities for the collaboration targets
  • The collaboration will combine Plexium's TPD technology platform with AbbVie's extensive neuroscience capabilities to discover novel therapies against drug targets for neurological diseases

Ref: PRNewswire | Image: Abbvie

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions